Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects (N=60)
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
To assess the pharmacokinetic characteristics of valsartan and S-amlodipine after single oral
administration of Exforge tab. 10/160mg, a combination formulation of valsartan and
amlodipine as reference drug and Lodivixx tab
Phase:
Phase 1
Details
Lead Sponsor:
Hanlim Pharm. Co., Ltd.
Treatments:
Amlodipine Amlodipine, Valsartan Drug Combination Valsartan